Hi Boffin,I agree with you. Partnering/licensing discussions...

Hi Boffin,

I agree with you. Partnering/licensing discussions have been going on for years, not just months.

Following the Advanz deal, there was a lot of speculation when the next one was coming. My gut feeling was that it wouldn’t be until after Interim 1 readout. A massive de-risk on this trial & I think that is what you are reading into this too? Raising $20 million is nothing to be sneezed at.

The language has certainly changed in presentations regarding focusing on further licensing deals, & having that cash backing is important for us, both for trial continuation & the bargaining opportunity.

Having multiple interested parties is also a blessing, but I think that this also should be reflected in the hard yards the company have put in to create the interest. Not only for FSGS, but other opportunities for drug development for DMX-200 & what is in our ‘data room’ already.

I’m not even going to go into other indications for the drug, other than the IP we hold, but it’s not just CKD as an umbrella diagnosis that DMX-200 may be useful in as an anti-inflammatory & anti-fibrotic drug. Lung fibrosis another (ie ILD) & the interest with the COVID-19 trials, plus more. It’s not just FSGS.

I was chatting to a friend recently about huge cash burn in a Ph3 in another stock…one that is not a rare disease, and from my understanding would require 2 Ph3 trials with a much larger cohort to achieve regulatory approval with the FDA.

The benefits of Orphan Drug status & going down this pathway first, should be apparent to people now. Then a paediatric population approved in the trial, could be more to come than just accelerated approval from the FDA. Rare Disease in Paediatric population & that just adds value, and also another treatment option for kids.

Holding off on DKD, that’s OK because there are other treatments available. I believe there would be added benefit on top of SOC (SGLT2i inhibitors have been allowed on our trials since Ph2B DKD trial as long as patients on a stable dose in the run in period).

Rare Disease opportunities for Pharma Cos provide benefits in costing drugs & also then holding other IP to develop prior to the exclusivity period & patent ending. I believe there are also tax benefits. I’m sure you would be aware already.

No surprise they have used NEU as a case study, although different indication in Orphan disease & more in the pipeline for other rare neuro diseases.

My point is they can’t do everything right now, I’m truly amazed at what DXB have achieved thus far. A $20 mill raise is nothing in the big scheme of things for a Ph3 trial, but will see us through to the next inflection point (where early commercialisation is possible).

Anyway, I think in the next few months it is entirely possible. When? Who knows, could be sooner rather than later now.